PL3458480T3 - Przeciwciało skierowane przeciwko receptorowi podtypu beta dla endoteliny - Google Patents

Przeciwciało skierowane przeciwko receptorowi podtypu beta dla endoteliny

Info

Publication number
PL3458480T3
PL3458480T3 PL17734032T PL17734032T PL3458480T3 PL 3458480 T3 PL3458480 T3 PL 3458480T3 PL 17734032 T PL17734032 T PL 17734032T PL 17734032 T PL17734032 T PL 17734032T PL 3458480 T3 PL3458480 T3 PL 3458480T3
Authority
PL
Poland
Prior art keywords
endotelin
type
targeted against
antibody targeted
against beta
Prior art date
Application number
PL17734032T
Other languages
English (en)
Inventor
Didier Boquet
Frédéric Ducancel
Amaury HERBET
Narciso COSTA
Jean-Philippe Hugnot
Original Assignee
Commissariat à l'énergie atomique et aux énergies alternatives
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat à l'énergie atomique et aux énergies alternatives filed Critical Commissariat à l'énergie atomique et aux énergies alternatives
Publication of PL3458480T3 publication Critical patent/PL3458480T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17734032T 2016-06-24 2017-06-22 Przeciwciało skierowane przeciwko receptorowi podtypu beta dla endoteliny PL3458480T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1655915A FR3053042B1 (fr) 2016-06-24 2016-06-24 Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
EP17734032.0A EP3458480B1 (en) 2016-06-24 2017-06-22 Antibody directed against the endothelin receptor beta sub-type
PCT/EP2017/065442 WO2017220739A1 (en) 2016-06-24 2017-06-22 Antibody directed against the endothelin receptor beta sub-type

Publications (1)

Publication Number Publication Date
PL3458480T3 true PL3458480T3 (pl) 2021-09-20

Family

ID=57583133

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17734032T PL3458480T3 (pl) 2016-06-24 2017-06-22 Przeciwciało skierowane przeciwko receptorowi podtypu beta dla endoteliny

Country Status (10)

Country Link
US (1) US11312780B2 (pl)
EP (1) EP3458480B1 (pl)
JP (2) JP7640220B2 (pl)
DK (1) DK3458480T3 (pl)
ES (1) ES2865300T3 (pl)
FR (1) FR3053042B1 (pl)
HU (1) HUE053695T2 (pl)
PL (1) PL3458480T3 (pl)
PT (1) PT3458480T (pl)
WO (1) WO2017220739A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3053042B1 (fr) * 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations
FR3077574B1 (fr) 2018-02-07 2022-04-01 Commissariat Energie Atomique Anticorps dirige contre le sous-type a des recepteurs aux endothelines et ses utilisations.
EP4662240A2 (fr) * 2023-02-09 2025-12-17 Commissariat à l'Energie Atomique et aux Energies Alternatives Fragment fab mutant pour l'obtention de conjugués mono- ou bi-fonctionnalisés site-spécifiques
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
WO2024209089A1 (en) 2023-04-07 2024-10-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
WO2025101890A1 (en) * 2023-11-10 2025-05-15 Yale University Compositions and methods of treating disease
FR3155708A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
FR3155709A1 (fr) * 2023-11-27 2025-05-30 Skymab Biotherapeutics Conjugue anticorps-medicament et ses utilisations
CN118580350A (zh) * 2024-08-07 2024-09-03 上海交通大学医学院附属仁济医院 一种神经小脑肽cbln1特异性单克隆抗体及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
WO2006009890A2 (en) * 2004-06-17 2006-01-26 The Regents Of The University Of California Methods and compositions for producing insulin sensitization
FR2965810B1 (fr) * 2010-10-06 2012-12-28 Commissariat Energie Atomique Anticorps antagoniste du sous-type b des recepteurs aux endothelines et ses utilisations
JP2012111706A (ja) 2010-11-24 2012-06-14 Sekisui Chem Co Ltd モノクローナル抗体、並びに、ハイブリドーマ
JP6251682B2 (ja) * 2011-10-28 2017-12-20 ジェネンテック， インコーポレイテッド メラノーマ治療の治療の組み合わせ及び方法
FR3053042B1 (fr) * 2016-06-24 2018-08-10 Commissariat A L'energie Atomique Et Aux Energies Alternatives Anticorps dirige contre le sous-type b des recepteurs aux endothelines et ses utilisations

Also Published As

Publication number Publication date
ES2865300T3 (es) 2021-10-15
US11312780B2 (en) 2022-04-26
JP2019528041A (ja) 2019-10-10
FR3053042A1 (fr) 2017-12-29
US20190185574A1 (en) 2019-06-20
JP2022095888A (ja) 2022-06-28
DK3458480T3 (da) 2021-04-19
EP3458480A1 (en) 2019-03-27
EP3458480B1 (en) 2021-01-27
WO2017220739A1 (en) 2017-12-28
FR3053042B1 (fr) 2018-08-10
JP7640220B2 (ja) 2025-03-05
PT3458480T (pt) 2021-04-28
HUE053695T2 (hu) 2021-07-28

Similar Documents

Publication Publication Date Title
IL280766A (en) Antibodies directed against programmed death- 1 (pd-1)
IL263834A (en) Anti-pd-l1 antibodies
IL269002A (en) Antibodies against pd-l1
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
DK3411410T3 (da) Pd-1-antistoffer
EP3498840A4 (en) ANTI-LAG-3 ANTIBODIES
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
DK3334824T3 (da) Pd-1-antistoffer
PT3354729T (pt) Anticorpo anti-garp
DK3344654T3 (da) Anti-lag-3-antistoffer
PL3458480T3 (pl) Przeciwciało skierowane przeciwko receptorowi podtypu beta dla endoteliny
PT3101032T (pt) Onjugado de anticorpo anti-her2-fármaco
DK3350218T5 (da) Polyomavirus-neutraliserende antistoffer
LT3292153T (lt) Cd30xcd16a antikūno derinys su antagonistiniu antikūnu prieš pd-1 skirtas terapijai
DK3250593T3 (da) Anti-transthyretin-antistoffer
IL256099A (en) Antibody
IL291164A (en) Anti-nme antibody
BR112016022040A2 (pt) aparelho de fixação.
PL3092003T3 (pl) Nowe przeciwciało przeciw netrynie-1
EP3523315A4 (en) INHIBITORS OF THE GLUCOCORTICOID RECEPTOR
EP3520638A4 (en) UNDERWEAR
DK3154587T3 (da) Konjugater omfattende et anti-egfr1-antistof
DK3452515T3 (da) Her-2-bindende antistoffer
DK3484921T3 (da) Anti-IL-22R antistoffer
EP3507303C0 (en) CD20 ANTIBODY